Johanna Vappiani

TL;DR: It is found that steady-state gene expression primarily requires BD1, whereas the rapid increase of gene expression induced by inflammatory stimuli requires both BD1 and BD2 of all BET proteins, which may guide future BET-targeted therapies.

TL;DR: “multiplexed proteome dynamics profiling” (mPDP), a mass-spectrometry-based approach combining dynamic-SILAC labeling with isobaric mass tagging for multiplexed analysis of protein degradation and synthesis, highlights the potential of mPDP to identify dynamically controlled degradation mechanisms in cellular systems.

TL;DR: In this paper, the depletion of 15 structurally diverse drugs by 25 representative strains of gut bacteria revealed 70 bacteria-drug interactions, 29 of which had not to our knowledge been reported before.

TL;DR: This study modified BET bromodomain inhibitors, an epigenetic-based therapy, to create functionally conserved compounds that are amenable to click chemistry and can be used as molecular probes in vitro and in vivo, providing a potential framework for the preclinical assessment of a wide range of drugs.

TL;DR: Tissue thermal proteome profiling (tissue-TPP), which measures binding of small-molecule drugs to proteins in tissue samples from drug-treated animals by detecting changes in protein thermal stability using quantitative mass spectrometry, is introduced.